 |
 |  |
        |
 Press Release: April 23, 2008 Romark Laboratories, a privately held biopharmaceutical company, today announced that data from studies of nitazoxanide in chronic hepatitis C virus (HCV) infection are being communicated in four presentations made at the 43rd Annual Meeting of the European Association for the Study of the Liver (EASL), held in Milan, Italy this week. Romark Laboratories Initiates Phase II Study Of Nitazoxanide In Treatment-Naïve Patients With Chronic Hepatitis C Genotype 1 Press Release: April 18, 2008 Romark Laboratories, a privately held biopharmaceutical company, today announced that it has begun enrolling patients in a U.S. clinical trial to evaluate nitazoxanide for the treatment of chronic hepatitis C. Romark Laboratories Names Emmet B. Keeffe, M.D. Vice President and Chief Medical Officer Press Release: January 7, 2008 Romark Laboratories, L.C., a privately-owned biotechnology company, today announced that Emmet B. Keeffe, M.D., M.A.C.P., has joined the Company as Vice President and Chief Medical Officer. Romark Laboratories Raises $18 Million in Institutional Financing Press Release: December 21, 2007 Romark Laboratories, L.C., a privately-owned biotechnology company, today announced the closing of an $18 million institutional financing with the D.E. Shaw Group. Phase II Study Shows that Nitazoxanide Significantly Improves Response to Standard of Care in Patients with Chronic Hepatitis C Press Release: November 2, 2007 Romark Laboratories, a privately-owned biotechnology company, today announced results of a randomized phase II clinical trial showing that 79% of interferon-naïve patients with chronic hepatitis C genotype 4 receiving nitazoxanide plus the standard of care had a sustained virologic response (SVR), or undetectable level of virus, 12 weeks following treatment, compared to 43% of patients receiving the standard of care without nitazoxanide. Romark Initiates Clinical Trial of Alinia® for Chronic Hepatitis C in the United States Press Release: August 15, 2007 Romark Laboratories announced that it has initiated a phase II clinical trial of Alinia® (nitazoxanide) for treating chronic hepatitis C in the United States. Romark Completes Financing with D. E. Shaw Group Press Release: May 14, 2007 Romark Laboratories announced that it has completed a $27 million financing with Laminar Direct Capital, a member of the D. E. Shaw Group. The financing was structured as a sale of senior secured notes and equity units. Merrill Lynch acted as placement agent for the transaction. Romark Drug Discovery Research Presented at 20th International Conference on Antiviral Research Press Release: May 3, 2007 Romark Laboratories announced that data generated from its antiviral drug discovery program was communicated as part of two separate oral presentations made during the course of the 20th International Conference on Antiviral Research held this week in Palm Springs, California. |
 |
 |
||